ArticlePloS one2026
Differential effects of ginsenosides on Ca2+ regulation in rotenone-treated neuronal and microglial cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is one of the most common neurodegenerative disorders, and the pesticide rotenone is widely used to model Parkinson's disease in experimental studies. Rotenone-induced mitochondrial dysfunction is associated with oxidative stress and intracellular Ca2+ ([Ca2+]ᵢ) dysregulation in neuronal systems. L-type Ca2+ channels (LTCCs) contribute to Ca² ⁺ influx under oxidative stress conditions, but pharmacological inhibition of LTCCs is limited by cardiovascular side effects. Phospholipase D (PLD) has also been implicated in cellular stress-associated signaling pathways. Ginsenosides are known to influence Ca² ⁺ -related signaling; however, differences among ginsenosides in neuronal and microglial Ca² ⁺ regulation have not been fully characterized. Therefore, this study aimed to investigate the effects of ginsenosides on intracellular Ca² ⁺ homeostasis and oxidative stress of rotenone-exposed SH-SY5Y neuronal cells and BV2 microglial cells. Cell viability, superoxide dismutase (SOD) activity, interleukin-6 (IL-6) levels, intracellular Ca² ⁺ influx, and malondialdehyde (MDA) levels were evaluated. Intracellular Ca² ⁺ was measured using Fura-2 AM ratiometric fluorescence analysis. The effects of ginsenosides Rg1, Rg2, and Rd were examined using pharmacological inhibitors targeting PLD, LTCCs, and protein kinase A (PKA). Rotenone reduced cell viability and SOD activity, while increasing IL-6 levels, [Ca2+]ᵢ influx, and MDA levels in both cell types. Treatment with ginsenosides immediately before rotenone exposure attenuated rotenone-induced increases in [Ca2+]ᵢ and MDA levels. Ca² ⁺ responses in both SH-SY5Y and BV2 cells were sensitive to PLD inhibition. In SH-SY5Y cells, responses were additionally sensitive to LTCC inhibition, whereas BV2 cells showed weaker LTCC-associated pharmacological responses. Rd showed broader pharmacological sensitivity involving PLD-, LTCC-, and PKA-associated components, whereas Rg1 and Rg2 showed predominantly PLD-associated response patterns. These findings suggest that ginsenosides differentially modulate rotenone-associated Ca² ⁺ dysregulation through PLD-associated pharmacological pathways in a cell type-dependent manner. Overall, the present findings demonstrate distinct pharmacological response profiles among structurally different ginsenosides under rotenone-induced oxidative stress conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.